Satellos Bioscience Inc.

DB:0ITA Stock Report

Market Cap: €76.5m

Satellos Bioscience Management

Management criteria checks 1/4

Satellos Bioscience's CEO is Frank Gleeson, appointed in Mar 2018, has a tenure of 6.75 years. total yearly compensation is CA$1.93M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 3.36% of the company’s shares, worth €2.57M. The average tenure of the management team and the board of directors is 1.6 years and 3 years respectively.

Key information

Frank Gleeson

Chief executive officer

CA$1.9m

Total compensation

CEO salary percentage20.7%
CEO tenure6.8yrs
CEO ownership3.4%
Management average tenure1.6yrs
Board average tenure3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Frank Gleeson's remuneration changed compared to Satellos Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$29m

Jun 30 2024n/an/a

-CA$23m

Mar 31 2024n/an/a

-CA$21m

Dec 31 2023CA$2mCA$398k

-CA$16m

Sep 30 2023n/an/a

-CA$14m

Jun 30 2023n/an/a

-CA$13m

Mar 31 2023n/an/a

-CA$11m

Dec 31 2022CA$338kCA$260k

-CA$11m

Sep 30 2022n/an/a

-CA$9m

Jun 30 2022n/an/a

-CA$18m

Mar 31 2022n/an/a

-CA$17m

Dec 31 2021CA$1mCA$226k

-CA$16m

Sep 30 2021n/an/a

-CA$13m

Jun 30 2021n/an/a

-CA$2m

Mar 31 2021n/an/a

-CA$2m

Dec 31 2020CA$192kCA$192k

-CA$2m

Dec 31 2019CA$180kCA$180k

-CA$2m

Compensation vs Market: Frank's total compensation ($USD1.36M) is above average for companies of similar size in the German market ($USD473.16K).

Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.

CEO

Frank Gleeson (69 yo)

6.8yrs

Tenure

CA$1,926,547

Compensation

Mr. Francis Gleeson, also known as Frank, B.B.A., M.B.A., is a Co-Founder of Satellos Bioscience Inc. He serves as Chief Executive Officer of Satellos Bioscience Inc. since March 2018. He serves as Directo...

Leadership Team

NamePositionTenureCompensationOwnership
Francis Gleeson
Co-Founder6.8yrsCA$1.93m3.36%
€ 2.6m
Elizabeth Williams
CFO & Corporate Secretary1.3yrsCA$741.42k0.035%
€ 26.9k
Philip Lambert
Chief Scientific Officer1.9yrsCA$1.45mno data
William Jarosz
Executive Director3.3yrsCA$216.74k1.51%
€ 1.2m
Warren Whitehead
Head of Corporate Strategy1.3yrsCA$444.38kno data
Michael Cross
Chief Business Officer1.3yrsCA$745.80k0.0037%
€ 2.9k
Michael Rudnicki
Co-Founder & Chief Discovery Officerno dataCA$120.00k2.73%
€ 2.1m
J. Hall
Senior Vice President of Finance & Administration3.3yrsno data0.070%
€ 53.9k
Michael Liggett
Strategic Advisor3.3yrsCA$44.48kno data
Desiree Chan
Chief of Staffno datano datano data
Courtney Wells
Senior Vice President of Clinical Development Operations1.1yrsno datano data
Ryan Mitchell
Senior Vice President of Medical & Scientific Affairsless than a yearno datano data

1.6yrs

Average Tenure

63yo

Average Age

Experienced Management: 0ITA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Francis Gleeson
Co-Founder12.4yrsCA$1.93m3.36%
€ 2.6m
William Jarosz
Executive Director3.3yrsCA$216.74k1.51%
€ 1.2m
Franklin Berger
Independent Director1.5yrsCA$47.41k6.65%
€ 5.1m
Geoff MacKay
Independent Chairman of the Board of Directors6.4yrsCA$87.84k0.22%
€ 171.3k
William McVicar
Independent Director3.3yrsCA$68.27k0.022%
€ 16.8k
Brian Bloom
Independent Director6.8yrsno data1.3%
€ 995.9k
Adam Mostafa
Independent Director3yrsCA$93.58kno data
Jordan Dubow
Chair of Clinical Advisory Board & Chief Medical Advisorless than a yearno datano data
Ronald Cohn
Member of Clinical Advisory Boardless than a yearno datano data
Rima Al-awar
Independent Director3yrsCA$69.28kno data
Nicholas Johnson
Member of Clinical Advisory Boardless than a yearno datano data
Perry Shieh
Member of Clinical Advisory Boardless than a yearno datano data

3.0yrs

Average Tenure

62yo

Average Age

Experienced Board: 0ITA's board of directors are considered experienced (3 years average tenure).